17.27

2.43% 0.41

Pre-market: 17.26 -0.010 -0.06%

Monte Rosa Therapeutics Inc (GLUE)

Overview News Price History Option Chain Financials Why GLUE Down? Discussions Forecast

Monte Rosa Therapeutics Inc stock is traded at $17.27, with a volume of 521.32K. It is up +2.43% in the last 24 hours and up +43.92% over the past month. Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Previous Close:

$16.86

Open:

$16.84

24h Volume:

521.32K

Relative Volume:

0.35

Market Cap:

$1.12B

Revenue:

Net Income/Loss:

$-130.41M

P/E Ratio:

-7.7098

EPS:

-2.24

Net Cash Flow:

$-67.76M

1W Performance:

+8.01%

1M Performance:

+43.92%

6M Performance:

+274.62%

1Y Performance:

+86.90%

1-Day Range:

$16.57

$17.63

1-Week Range:

$15.21

$17.63

52-Week Range:

$3.5001

$17.63

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name

Monte Rosa Therapeutics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

617-949-2643

Address

321 HARRISON AVENUE, BOSTON

Employee

147

Twitter

Next Earnings Date

Latest SEC Filings

GLUE's Discussions on Twitter

Compare GLUE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GLUE Monte Rosa Therapeutics Inc	17.27	1.10B	0	-130.41M	-67.76M	-2.24
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-15-24	Initiated	Wedbush	Outperform
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-13-22	Initiated	UBS	Buy
Aug-15-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Credit Suisse	Neutral
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Oct-14-21	Initiated	SVB Leerink	Mkt Perform

View All

Monte Rosa Therapeutics Inc Stock (GLUE) Latest News

Dec 04, 2025

Monte Rosa Therapeutics (NASDAQ:GLUE) Sets New 52-Week HighHere's Why - MarketBeat

Dec 04, 2025

Dec 03, 2025

Monte Rosa Therapeutics stock hits 52-week high at $16.66 By Investing.com - Investing.com India

Dec 03, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st

Dec 03, 2025

Dec 02, 2025

Monte Rosa Therapeutics (GLUE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 02, 2025

Dec 01, 2025

Improved Revenues Required Before Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock's 26% Jump Looks Justified - 富途牛牛

Dec 01, 2025

Nov 30, 2025

Monte Rosa: Looking Mispriced After Big Pharma Validation (NASDAQ:GLUE) - Seeking Alpha

Nov 30, 2025

Nov 28, 2025

How Monte Rosa Therapeutics Inc. stock reacts to inflationary pressuresQuarterly Earnings Summary & Real-Time Buy Signal Notifications - moha.gov.vn

Nov 28, 2025

Nov 27, 2025

Monte Rosa Therapeutics Jumps 124.9% in 2025 But Are Investors Getting Ahead of Themselves - Yahoo Finance

Nov 27, 2025

Nov 26, 2025

Hillsdale Investment Management Inc. Makes New $271,000 Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat

Nov 26, 2025

Nov 25, 2025

Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month HighShould You Buy? - MarketBeat

Nov 25, 2025

Nov 23, 2025